RxDoctor Payments Data

Bassel Ramadan, MD

Critical Care Medicine · Dade City, FLNPI 1487603361

Payments from drug & device makers

$1,704in general payments, 2019–2025

Across 68 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$456
  • AstraZeneca$286
  • Inspire Medical Systems, Inc.$216
  • Verona Pharma, Inc.$132
  • Sanofi$126
  • Regeneron Healthcare Solutions, Inc.$125
  • plus $363 from 12 others

What the payments were for

  • Consulting fees$503%
  • Food & beverage$1,63496%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,704 in reported general payments places this provider in the 75th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$316,269
Medicare patients
501
Services billed
2,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter324$263,662
Breztri AerosphereBudesonide/Glycopyr/Formoterol191$133,352
Fasenra PenBenralizumab18$107,682
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$31,807
Spiriva RespimatTiotropium Bromide44$29,859
EliquisApixaban21$18,248
Breo ElliptaFluticasone/Vilanterol43$17,270
SymbicortBudesonide/Formoterol Fumarate48$15,563
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$12,373
Combivent RespimatIpratropium/Albuterol Sulfate17$10,332
Albuterol Sulfate HfaAlbuterol Sulfate300$6,839
Incruse ElliptaUmeclidinium Bromide16$5,379
Roflumilast26$3,040
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,086
Montelukast Sodium183$1,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$456$318,117432 claims
AstraZenecaBreztri Aerosphere, Symbicort$286$148,916239 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$25$52,56385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Dade City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →